Recipients of blood or blood products “at vCJD risk”

Five year calendar period of birth [19´ 0-19´ 4 or 19´ 5-19´ 9]

Sex

Codon 129 phenotype (to date: all methionine homozygote)

Month and year of vCJD infected donation

Month and year of vCJD recipient’s "vCJD infected blood transfusion" from donor

Number and type of at-vCJD risk units transfused (had red cells been leucodepleted?)

Month and year of vCJD donor’s

i) vCJD onset

ii) Notification to National CJD Surveillance Unit

iii) Death

iv) vCJD diagnosis

vCJD recipient:

5-year calendar period of birth [19´ 0-19´ 4 or 19´ 5-19´ 9]

Sex

Codon 129 phenotype (whether vCJD recipient is methionine homozygote)

Month and year of vCJD recipient’s

i) vCJD onset

iia) Notification to National CJD Surveillance Unit

iib) Identification as recipient of blood transfusion/products from a donor who subsequently developed vCJD

iii) Death, and

iv) vCJD diagnosis

For each known other recipient (of potentially vCJD incubating blood transfusion or products from same vCJD donor):

Five year calendar period of birth [19´ 0-19´ 4 or 19´ 5-19´ 9] of recipient at risk of vCJD 

Sex of recipient at risk of vCJD

Codon 129 phenotype (whether recipient of potentially vCJD incubating blood transfusion or products is methionine homozygote)

Month and year of receipt of potentially vCJD infected blood transfusion or products

Survival status of recipient (if deceased: month and year of death and whether postmortem or tonsil biopsywas performed)

Status of recipient re stored operative tissue testable for abnormal PrP^SC (month and year of operation, location of testable operative tissue)